NDLI: Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients

Content Provider	Springer Nature Link
Author	Plakhins, Grigorijs Irmejs, Arvids Gardovskis, Andris Subatniece, Signe Liepniece Karele, Inta Purkalne, Gunta Teibe, Uldis Trofimovics, Genadijs Miklasevics, Edvins Gardovskis, Janis
Copyright Year	2013
Abstract	BRCA1-associated breast cancer is considered an unique clinical entity with its own specific histopathological characteristics. Several recently published large studies have shown that overall survival of BRCA1 mutation carriers having breast cancer is similar to sporadic breast cancer patients. It was also suggested that better response to chemotherapy is one of the most important factors that improves the clinical outcome of breast cancers with unfavorable histopathological subtypes in BRCA1 mutation carriers. Adjuvant! Online and PREDICT are web-based prognostic tools that estimate the survival benefit of adjuvant chemotherapy in primary breast cancer patients. These tools have been extensively validated in different populations; however, the accuracy of the predictions made by Adjuvant! Online and PREDICT among BRCA1 mutation carriers has not yet been investigated. In this study we have found, that predictions of overall and breast cancer-specific survival obtained from Adjuvant! Online and PREDICT were significantly lower than the observed survival percentages in the study population [predicted—observed difference for 10–year overall survival: −9.75 %, P < 0.0001 (Adjuvant! Online); −10.21 %, P < 0.0001 (PREDICT)]. Thus this study suggests that Adjuvant! Online and PREDICT should be used with caution in this group of patients. Further updating of adjuvant therapy benefit calculation tools by inclusion of the information about inherited genetic alterations should be considered to improve the performance of the prognostic programs among hereditary breast cancer patients.
Starting Page	683
Ending Page	689
Page Count	7
File Format	PDF
ISSN	13899600
Journal	Familial Cancer
Volume Number	12
Issue Number	4
e-ISSN	15737292
Language	English
Publisher	Springer Netherlands
Publisher Date	2013-05-03
Publisher Place	Dordrecht
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	BRCA1 Founder mutations Breast cancer Adjuvant chemotherapy Cancer Research Human Genetics Epidemiology Biomedicine general
Content Type	Text
Resource Type	Article
Subject	Genetics Cancer Research Genetics (clinical) Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia

Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer

High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer

Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer

BRCA1 founder mutations compared to ovarian cancer in Belarus

Two BRCA1/2 founder mutations in Jews of Sephardic origin

BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan

A high frequent BRCA1 founder mutation identified in the Greenlandic population

Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba

Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients

Similar Documents

Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia

Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer

High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer

Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer

BRCA1 founder mutations compared to ovarian cancer in Belarus

Two BRCA1/2 founder mutations in Jews of Sephardic origin

BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan

A high frequent BRCA1 founder mutation identified in the Greenlandic population

Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba

Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients